Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B

References

• Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol. Ther.28(2), 167–177 (2008).
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA295(1), 65–73 (2006).
   PubMed Web of Science ®Google Scholar
• Fattovich G. Natural history and prognosis of hepatitis B. Semin. Liver Dis.23(1), 47–58 (2003).
   PubMed Web of Science ®Google Scholar
• Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis b e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology139(2), 491–498 (2010).
   PubMed Web of Science ®Google Scholar
• VIREAD®, package insert. Gilead Sciences, Inc., Foster City, CA, USA (2010).
   Google Scholar
• Marcellin P, Heathcote EJ, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med.359(23), 2442–2455 (2008).
   PubMed Web of Science ®Google Scholar
• Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol. Int.2(2), 163–178 (2008).
   PubMed Web of Science ®Google Scholar
• Lok AS, Lai CL, Leung N et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology125(6), 1714–1722 (2003).
   PubMed Web of Science ®Google Scholar
• Chang TT, Lai CL, Chien RN et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol.19(11), 1276–1282 (2004).
   PubMed Web of Science ®Google Scholar
• Yuen MF, Seto WK, Chow DH et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antivir. Ther.12(8), 1295–1303 (2007).
   PubMed Web of Science ®Google Scholar
• Liaw YF, Gane E, Leung N et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology136(2), 486–495 (2009).
   PubMed Web of Science ®Google Scholar
• Hsu CW, Chen YC, Liaw YF et al. Prolonged efficacy and safety of 3 years of continuous telbivudine treatment in pooled data from Globe and 015 studies in chronic hepatitis B patients. Presented at: European Association for the Study of the Liver 2009 (EASL 2009). Copenhagen, Denmark, 22–26 April 2009.
   Google Scholar
• Marcellin P, Chang TT, Lim SG et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology48(3), 750–758 (2008).
   PubMed Web of Science ®Google Scholar
• Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology131(6), 1743–1751 (2006).
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Rose RE, Baldick CJ et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology49(5), 1503–1514 (2009).
   PubMed Web of Science ®Google Scholar
• Tenney DJ, Pokorowski KA, Rose RE et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. J. Hepatol.50(Suppl. 1), S10 (2009).
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J. Viral Hepat.16(3), 149–155 (2009).
   PubMed Web of Science ®Google Scholar
• Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin. Investig. Drugs18(11), 1655–1666 (2009).
   PubMed Web of Science ®Google Scholar
• Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology49(5 Suppl.), S122–S128 (2009).
   Web of Science ®Google Scholar
• Yatsuji H, Suzuki F, Sezaki H et al. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J. Hepatol.48(6), 923–931 (2008).
   PubMed Web of Science ®Google Scholar
• Sung JJ, Lai JY, Zeuzem S et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J. Hepatol.48(5), 728–735 (2008).
   PubMed Web of Science ®Google Scholar
• Poordad F, Chee GM. Viral resistance in hepatitis B: prevalence and management. Curr. Gastroenterol. Rep.12(1), 62–69 (2010).
   PubMedGoogle Scholar
• Sheldon J, Camino N, Rodes B et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir. Ther.10(6), 727–734 (2005).
   PubMed Web of Science ®Google Scholar
• Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology49(4), 1158–1165 (2009).
   PubMed Web of Science ®Google Scholar
• Delaney WE 4th, Ray AS, Yang H et al. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob. Agents Chemother.50(7), 2471–2477 (2006).
   PubMed Web of Science ®Google Scholar
• Fung S, Mazzulli T, Sherman M. Presence of rtA194T at baseline does not reduce efficacy to tenofovir (TDF) in patients with lamivudine (LAM)-resistant chronic hepatitis B [poster no. 880]. Presented at: 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2008). CA, USA, 31 October–4 November 2008.
   Google Scholar
• Snow-Lampart A, Chappell B, Sorbel J et al. Evaluation of potential virologic resistance in HBV polymerase among subjects with persistent viremia following up to 144 weeks of therapy with tenofovir DF. Presented at: 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010). Vienna, Austria, 14–18 April 2010.
   Google Scholar
• Snow-Lampart A, Chappell B, Curtis M et al. Resistance surveillance for up to 144 weeks in HBeAg+ and HBeAg- hepatitis B patients treated with tenofovir DF showed no relationship between virologic breakthrough and emergence of genotypic changes in HBV polymerase. Hepatology50(Suppl. 4), A480 (2009).
   Google Scholar
• Brunelle MN, Jacquard AC, Pichoud C et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology41(6), 1391–1398 (2005).
   PubMed Web of Science ®Google Scholar
• Qi X, Xiong S, Yang H, Miller M, Delaney WE. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir. Ther.12(3), 355–362 (2007).
   PubMed Web of Science ®Google Scholar
• Kitrinos K, Myrick F, Curtis M et al.In vitro tenofovir sensitivity of HBV populations from clinical specimens containing rtA181T/V and/or rtN236T. Hepatology50(Suppl. 4), A434 (2009).
   PubMedGoogle Scholar
• Pham PA, Gallant JE. Tenofovir disoproxil fumarate for the treatment of HIV infection (review). Expert Opin. Drug Metab. Toxicol.2(3), 459–469 (2006).
   PubMed Web of Science ®Google Scholar
• Marcellin P, Buti M, Krastev Z et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-negative patients with chronic hepatitis B (Study 102). Presented at: 13th International Symposium on Viral Hepatitis and Liver Disease. Washington DC, USA, 20–24 March 2009.
   Google Scholar
• Heathcote E, Gane EJ, De Man RA et al. Two year tenofovir disoproxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (Study 103). Presented at: 13th International Symposium on Viral Hepatitis and Liver Disease. Washington DC, USA, 20–24 March 2009.
   Google Scholar
• Marcellin P, Buti M, Krastev Z et al. Three years of tenofovir disoproxil fumarate (TDF) treatment in HBeAg-negative patients with chronic hepatitis B (Study 102); preliminary analysis. Presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston, MA, USA, 30 October–1 November 2009.
   Google Scholar
• Heathcote E, Gane EJ, De Man RA et al. Three years of tenofovir disoproxil (TDF) treatment in HBeAg-positive patients (HBeAg+) with chronic hepatitis B (Study 103), preliminary analysis. Presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston, MA, USA, 30 October–1 November 2009.
   Google Scholar
• Manns M, Jeffers L, Dalekos G et al. Safety and efficacy of 96 weeks of tenofovir disoproxil fumarate therapy in lamivudine experienced patients. Presented at: 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009). Copenhagen, Denmark, 22–26 April 2009.
   Google Scholar
• Hann HW, Chae HB, Dunn SR. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV). Hepatol. Int.2(2), 244–249 (2008).
   PubMedGoogle Scholar
• Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin. Gastroenterol. Hepatol.2(3), 266–272 (2004).
   PubMed Web of Science ®Google Scholar
• Manns M, Heathcote J, Marcellin P et al. Efficacy of tenofovir DF treatment in patients with a suboptimal response to adefovir dipivoxil. Presented at: 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010). Vienna, Austria, 14–18 April 2010.
   Google Scholar
• Levrero M, Cimino L, Lampertico P et al. Tenofovir DF (TDF) for chronic hepatitis B patients with suboptimal response to adefovir (ADV) or ADV/LAM treatment: interim analysis of the multicenter prospective open label study OptiB. Presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston, MA, USA, 30 October–1 November 2009.
   Google Scholar
• Sarin N, Yim C, Feld JJ et al. Tenofovir is effective salvage therapy for nucleoside-resistant Hepatitis B. Presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston, MA, USA, 30 October–1 November 2009.
   Google Scholar
• Alazawi W, Cottle R, Ross V et al. Substitution of adefovir for tenofovir in patients with chronic HBV receiving combination therapy who have incomplete control or virological breakthrough – is it worthwhile? Presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston, MA, USA, 30 October–1 November 2009.
   Google Scholar
• van Bömmel F, Zöllner B, Sarrazin C et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology44(2), 318–325 (2006).
   PubMed Web of Science ®Google Scholar
• Santos SA, Uriel AJ, Park JS et al. Effect of switching to tenofovir with emtricitabine in patients with chronic hepatitis B failing to respond to an adefovir-containing regimen. Eur. J. Gastroenterol. Hepatol.18(12), 1247–1253 (2006).
   PubMed Web of Science ®Google Scholar
• Schildgen O, Sirma H, Funk A et al. Variant of hepatitis B virus with primary resistance to adefovir. N. Engl. J. Med.354(17), 1807–1812 (2006).
   PubMed Web of Science ®Google Scholar
• van Bömmel F, de Man RA, Wedemeyer H et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology51(1), 73–80 (2010).
   PubMed Web of Science ®Google Scholar
• Leemans WF, Niesters HG, van der Eijk AA, Janssen HL, Schalm SW, de Man RA. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. Eur. J. Gastroenterol. Hepatol.20(8), 773–777 (2008).
   PubMed Web of Science ®Google Scholar
• Buti M, Hadziyannis S, Mathurin P et al. Two years safety and efficacy of tenofovir disoproxil fumarate (TDF) in patients with HBV-induced cirrhosis. Presented at: 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009). Copenhagen, Denmark, 22–26 April 2009.
   Google Scholar
• Del Poggio P, Zaccanelli M, Oggionni M, Colombo S, Jamoletti C, Puhalo V. Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HbeAg-negative hepatitis B. World J. Gastroenterol.13(30), 4096–4099 (2007).
   PubMedGoogle Scholar
• Choe WH, Kwon SY, Kim BK et al. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. Liver Int.28(6), 814–820 (2008).
   PubMedGoogle Scholar
• Liaw Y, Lee C, Akarca US et al. Interim results of a double-blind, randomized Phase 2 study of the safety of tenofovir disoproxil fumarate, emtricitabine plus tenofovir disoproxil fumarate, and entecavir in the treatment of chronic hepatitis B subjects with decompensated liver disease. Presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston, MA, USA, 30 October–1 November 2009.
   Google Scholar
• Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J. Hepatol.48(3), 391–398 (2008).
   PubMed Web of Science ®Google Scholar
• Berg T, Moller B, Trinh H et al. Tenofovir disoproxil fumarate (TDF) versus emtricitabine plus TDF (FTC/TDF) for treatment of chronic hepatitis B (CHB) in patients with persistent viral replication receiving adefovir dipivoxil. Presented at: 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009). Copenhagen, Denmark, 22–26 April 2009.
   Google Scholar
• Petersen J, Lutgehetmann M, Zoulim F et al. Entecavir and tenofovir combination therapy in chronic hepatitis B: rescue therapy in patients with advanced fibrosis and multiple previous treatment failures. Results from an international multicenter cohort study. Presented at: 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2009). Boston, MA, USA, 30 October–1 November 2009.
   Google Scholar
• Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology49(5 Suppl.), S185–S195 (2009).
   Web of Science ®Google Scholar
• Gitman MD, Hirschwerk D, Baskin CH, Singhal PC. Tenofovir-induced kidney injury. Expert Opin. Drug Saf.6(2), 155–164 (2007).
   PubMed Web of Science ®Google Scholar
• Buti M, Brosa M, Casado MA, Rueda M, Esteban R. Modeling the cost–effectiveness of different oral antiviral therapies in patients with chronic hepatitis B. J. Hepatol.51(4), 640–646 (2009).
   PubMedGoogle Scholar
• Jenh AM, Thio CL, Pham PA. Tenofovir for the treatment of hepatitis B virus. Pharmacotherapy29(10), 1212–1227 (2009).
   PubMed Web of Science ®Google Scholar